SCHEMBL24628532

SCHEMBL24628532

CN(C)S(=O)(=O)c1ccc(S(=O)(=O)Nc2ccccc2C2CCNCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCOLN2 Q8IZK6 1/20 0.45
LIMK2 P53671 1/20 0.43
ALDH1A1 P00352 4/20 0.42
HTR2C P28335 4/20 0.41
HTR6 P50406 6/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR2B P41595 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
THRB P10828 1/20 0.39
USP2 O75604 1/20 0.39
POLB P06746 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23057137 0.88 MCOLN2 (0.52) MCOLN2ALDH1A1LMNAMAPTMEN1
SCHEMBL30936702 0.81 MCOLN2 (0.43) MCOLN2LIMK2ALDH1A1HTR2CHTR6
SCHEMBL29772906 0.81 MCOLN2 (0.46) MCOLN2LIMK2ALDH1A1LMNASMN1; SMN2
SCHEMBL23570048 0.78 MCOLN2 (0.43) MCOLN2LIMK2ALDH1A1HTR2CLMNA
SCHEMBL29932067 0.78 MCOLN2 (0.46) MCOLN2ALDH1A1LMNAMEN1TSHR
SCHEMBL4679800 0.77 HTR2C (0.51) HTR2CHTR6KEAP1L3MBTL1
SCHEMBL24628794 0.77 SLC6A2 (0.46) MCOLN2ALDH1A1HTR6LMNAMAPT
SCHEMBL29772897 0.77 SLC6A2 (0.46) MCOLN2ALDH1A1HTR6LMNAMAPT
Hydrochloric Acid SCHEMBL7676942 0.76 HTR2C (0.53) HTR2CHTR6KEAP1L3MBTL1
SCHEMBL28867493 0.76 NMT1 (0.38) MCOLN2LIMK2HTR2CHTR6HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299348-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. 2024-09-12 US disclosed
WO-2022150461-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. (US) 2022-07-14 WO disclosed
WO-2022150461-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299348-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE TRPM5, TRPM6, TRPM2 MCOLN2 10/4885LIMK2 1049/4885ALDH1A1 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.